Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaPB for Glycaemic Control in Type 2 Diabetes
NCT05836350Phase 4Not yet recruiting
- Sponsor
- Maastricht University
- Start
- Jun 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NaPB with Placebo (2 arms). Primary endpoint: Fasting Plasma Glucose Levels at 12 weeks. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05836350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836350.